Core Insights - The article discusses the investment thesis on Dell Technologies, focusing on AI server exposure and anticipated enterprise spending rebound as key drivers for potential upside [1]. Group 1: Company Analysis - Dell Technologies has been covered in previous analyses, with a focus on its AI server exposure leading to positive valuation support [1]. - The analyst has a background in quantitative research and financial modeling, emphasizing the importance of equity valuation and market trends in identifying investment opportunities [1]. Group 2: Investment Strategy - The approach combines rigorous risk management with a long-term perspective on value creation, aiming to provide actionable insights for investors [1]. - The analyst's experience includes leading teams in model validation and stress testing, which contributes to a deep understanding of fundamental and technical analysis [1].

Group 1 - The article discusses Dell Technologies' (DELL) performance and investment thesis, highlighting AI server exposure as a key driver for potential upside [1] - The analyst previously covered Dell in May and October 2025, noting varying degrees of success in their investment calls [1] - The May thesis focused on supportive valuations and anticipated a rebound in enterprise spending, which contributed to a positive outlook for the company [1] Group 2 - The analyst has over 20 years of experience in quantitative research, financial modeling, and risk management, emphasizing expertise in equity valuation and market trends [1] - The research approach combines rigorous risk management with a long-term perspective on value creation, aiming to provide actionable investment ideas [1] - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis to identify high-growth investment opportunities [1]

Core Viewpoint - The market is starting 2026 positively, with the S&P 500 maintaining last year's gains, but a significant rotation in large-cap stocks is anticipated this year [1]. Group 1 - The S&P 500 is holding onto last year's gains as 2026 begins [1]. - Investors are advised to prepare for a sizable rotation in the market, particularly among large-cap stocks [1]. - Gary Alexander has extensive experience in technology sectors, both on Wall Street and in Silicon Valley, influencing current industry themes [1].

Group 1: Hiring Trends in Big Tech - Energy-related hiring in Big Tech surged by 34% year-on-year in 2024, with last year's hiring remaining 30% higher than pre-AI levels of 2022 [1][2] - Microsoft has made over 570 energy-related hires since 2022, while Amazon leads with 605 hires, including its subsidiary AWS [5][6] - Google has added 340 energy-related hires since 2022, indicating a strategic focus on energy market innovation [7] Group 2: Importance of Energy for AI - Data centers accounted for approximately 1.5% of global electricity consumption in 2024, reflecting a 12% year-on-year increase over the last five years [2] - The demand for energy is expected to rise further as infrastructure builds out, posing significant challenges for Big Tech companies [3][4] Group 3: Strategic Acquisitions and Partnerships - Big Tech companies are acquiring energy-related firms and building their own energy supply to meet growing demands, with Alphabet set to acquire Intersect for $4.75 billion [8] - Meta has secured power purchase agreements with companies like Oklo, Vistra, and Terrapower, indicating a shift towards energy procurement [14][15] Group 4: Talent Market Dynamics - The competition for energy specialists is intensifying as tech companies seek talent with skills in energy strategy and grid connection, leading to a tight talent market [12] - Utilities may benefit from increased energy demand as tech companies turn to them for support rather than viewing them as acquisition targets [13]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - dsm-firmenich has appointed Nikeisha van Sleeuwen as Chief Human Resources Officer, effective April 1, 2026, succeeding Mieke Van de Capelle, who will retire after ten years of service [1][4]. Group 1: Appointment Details - Nikeisha van Sleeuwen currently serves as SVP Talent & Culture and Global Rewards at dsm-firmenich, bringing over 20 years of HR leadership experience [2]. - She has a proven track record in fostering talent and building inclusive teams across global functions [2]. - Nikeisha holds academic credentials from Ramapo College of New Jersey and Cornell ILR and has been with the company for nearly 20 years [3]. Group 2: Leadership Transition - Mieke Van de Capelle has led the HR function through significant transformation and integration at dsm-firmenich, leaving behind a strong HR organization [4]. - Under her leadership, the company made substantial progress in employee engagement and capability building [4]. - Mieke's retirement is set for March 31, 2026, after a decade of service [4]. Group 3: CEO's Remarks - Dimitri de Vreeze, CEO of dsm-firmenich, expressed delight in welcoming Nikeisha to the Executive Committee, highlighting her exceptional leadership qualities [5]. - He acknowledged Mieke's foundational role in the company and her focus on succession planning, which facilitated the appointment of an outstanding internal successor [5]. Group 4: Company Overview - dsm-firmenich is a leading innovator in nutrition, health, and beauty, with revenues exceeding €12 billion and operations in nearly 60 countries [6]. - The company employs around 30,000 people and focuses on creating sustainable solutions for a growing global population [6].

Core Insights - Tata Consultancy Services (TCS) has announced a strategic collaboration with AMD to enhance AI adoption in enterprises, modernize legacy systems, and create secure digital workplaces [1][2] Group 1: Collaboration Details - The partnership will focus on co-developing industry-specific AI and GenAI solutions by leveraging TCS's domain expertise and AMD's high-performance computing capabilities [2] - TCS and AMD will invest in talent development to create a pool of experts for next-generation AI solutions, with frameworks tailored for sectors like life sciences, manufacturing, and BFSI [2] - The collaboration aims to deliver accelerators and best practices to improve AI performance in both training and inference workloads [2] Group 2: Leadership Statements - Dr. Lisa Su, CEO of AMD, emphasized the need for high-performance computing and collaboration to unlock AI's potential across industries [3] - K. Krithivasan, CEO of TCS, highlighted the partnership as a significant step in scaling AI for enterprises, moving from experimentation to deployment [3] Group 3: Technological Integration - TCS will integrate AMD's Ryzen™ CPUs and EPYC™ CPUs, along with Instinct™ GPUs, to modernize hybrid cloud and high-performance computing environments [3][4] - The collaboration will utilize AMD's embedded computing portfolio to drive edge innovation and industrial digitalization [3][4] Group 4: Company Background - TCS has a workforce of 590,000 across 55 countries and has generated over US $30 billion in revenue for the fiscal year ending March 31, 2025 [7][8] - The company has a long history of innovation and has maintained partnerships with clients through various technology cycles since its inception in 1968 [6][7]

Core Viewpoint - RemeGen has entered a licensing agreement with AbbVie for RC148, which includes significant upfront and milestone payments, indicating strong market expectations for the drug's potential [1] Company Summary - RemeGen will receive an upfront payment of US$650 million and milestone payments of up to US$4.95 billion from AbbVie for the rights to develop, manufacture, and commercialize RC148 outside Greater China [1] - The licensing agreement is expected to alleviate RemeGen's cash position, which was RMB1.45 billion as of September 30, 2025 [2] Clinical Data Summary - RC148 demonstrated an overall response rate (ORR) of 61.9% and a disease control rate (DCR) of 100% in first-line PD-L1-positive NSCLC patients [2] - In combination with docetaxel for second/third-line NSCLC, RC148 showed an ORR of 66.7% and a median progression-free survival (mPFS) of 8.3 months [2] - The safety profile of RC148 is considered manageable, with clinical benefits observed across all subgroups [2] Industry Insights - The licensing-out activity in the China healthcare industry is expected to remain robust in 2026, particularly in the area of immuno-oncology (IO) [2] - The transaction reflects overseas recognition of RemeGen's R&D capabilities and highlights the competitive landscape of the PD-(L)1/VEGF market, with other companies like Pfizer also advancing their products [2]